Dapagliflozin + sitagliptin contains an active component as Dapagliflozin and sitagliptin. Dapagliflozin is a medication belonging to the class of drugs called sodium-glucose cotransporter 2 (SGLT2) inhibitors. This helps to lower blood glucose levels and reduce the overall blood sugar burden in the body. Sitagliptin is a medication classified as a dipeptidyl peptidase-4 (DPP-4) inhibitor. FDA approval date for Dapagliflozin is January 8, 2014 and for Sitagliptin is October 16, 2006

Dapagliflozin + sitagliptin is used to treat type 2 diabetes mellitus.

Dapagliflozin + sitagliptin can be administered orally in tablet form. The specific usage instructions may vary depending on the condition being treated and the form of the medication. Oral tablets are typically taken with water, as directed by the healthcare provider.

The combination of dapagliflozin and sitagliptin for type 2 diabetes can cause various side effects. Common side effects of dapagliflozin include genital and urinary tract infections, increased urination, dehydration, low blood pressure, and elevated cholesterol levels. Sitagliptin's common side effects include upper respiratory tract infections, headache, stomach upset, and joint pain.

Dapagliflozin can increase the risk of genital yeast infections and urinary tract infections, as well as potentially lead to dehydration and low blood pressure (hypotension) due to increased urination. It is also associated with a risk of diabetic ketoacidosis (DKA), a serious condition with elevated ketones in the blood, especially during episodes of acute illness or reduced insulin dosing. Additionally, dapagliflozin may cause acute kidney injury, requiring careful monitoring in individuals with kidney impairment or dehydration. Sitagliptin has warnings for pancreatitis, a rare but serious inflammation of the pancreas, and the risk of hypoglycemia when used with other diabetes medications.

It is crucial to inform healthcare providers of any pre-existing medical conditions, allergies, or medications being taken to avoid potential interactions and complications. Regular monitoring and follow-up appointments are essential to ensure proper management and minimize risks associated with Dapagliflozin + sitagliptin use. Patients should not drive or operate machinery if experiencing dizziness or drowsiness while on these medications. If any concerning symptoms occur, seek immediate medical attention and consult a healthcare professional for guidance on proper use and potential alternatives. Patients experiencing significant edema should consult their healthcare provider.

If you have prescribed dapagliflozin + sitagliptin for type 2 diabetes, follow your healthcare provider's instructions carefully. Monitor for unusual symptoms, such as genital or urinary infections, and stay hydrated to prevent dehydration. Be aware of signs of diabetic ketoacidosis and seek medical attention promptly if needed. If you have kidney impairment or use sitagliptin with other diabetes medications, be cautious about potential side effects. Regularly attend follow-up appointments and communicate openly with your healthcare provider about any concerns or questions for a successful and safe diabetes management journey. 

1. Mohsin Kazi et al., Development and optimization of sitagliptin and dapagliflozin loaded oral self-nanoemulsifying formulation against type 2 diabetes mellitus, [Revised on 28/12/2021] [Accessed on 19/07/2023], https://pubmed.ncbi.nlm.nih.gov/33345632/
2. Yue Sun et al., Effects of Dapagliflozin and Sitagliptin on Insulin Resistant and Body Fat Distribution in Newly Diagnosed Type 2 Diabetic Patients [Revised on 26/4/2020] [Accessed on 19/07/2023], https://pubmed.ncbi.nlm.nih.gov/32240122/

The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.